Cartilage Tissue Production Using Marker-Selected Chondrocyte Spheroids
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing cartilage tissue in vitro fail to replicate the essential matrix protein expression patterns of native cartilage, leading to suboptimal mechanical properties and limited therapeutic efficacy in treating cartilage defects.
Innovation Solution
The use of specific markers such as KAL1, CRTAC1, NRN1, and EBF3 to identify and select chondrocytes and spheroids of sufficient quality for cartilage tissue production, ensuring accurate expression of collagen II, aggrecan, and reduced collagen I, thereby enhancing the quality and purity of the extracellular matrix.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If chondrocytes are cultivated in monolayer culture to multiply cells, then cell quantity increases, but differentiation ability decreases and phenotypic stability is lost
Solution Approach 1:
The cultivation process is divided into distinct phases: monolayer culture for cell multiplication followed by spheroid formation for differentiation. This segmentation allows each phase to optimize for its specific function without compromising the other.
Solution Approach 2:
Chondrocytes are pre-multiplied in monolayer culture to achieve sufficient cell quantity before transitioning to spheroid formation. This preliminary action ensures adequate cell numbers are available for subsequent differentiation and transplantation.
2Quantity of substance
If cell aggregates are produced through standard cultivation methods, then cell quantity increases, but collagen II expression remains insufficient
Solution Approach 1:
The invention changes cultivation parameters by transitioning from monolayer to spheroid configuration and extending cultivation duration. These parameter changes induce proper collagen II expression while maintaining adequate cell quantities.
Solution Approach 2:
The cultivation period is extended beyond standard durations to allow sufficient time for collagen II synthesis and accumulation. This excessive action ensures adequate matrix production even with limited starting cell numbers.
3Reliability
If growth factors like TGF-β1-3 are added to culture medium to improve differentiation, then cartilage-like properties increase, but clinical safety concerns arise
Solution Approach 1:
The chondrocytes are cultured in autologous serum-containing medium, allowing them to self-regulate differentiation through naturally present factors. This eliminates the need for exogenous growth factors while maintaining cartilage-like properties and ensuring clinical safety.
4Quantity of substance
If biopsy samples are taken to obtain chondrocytes, then cell source is obtained, but cell number is limited and phenotypic instability occurs during cultivation
Solution Approach 1:
The cultivation process is segmented into monolayer expansion phase and spheroid formation phase. This segmentation allows initial cell multiplication followed by phenotypic stabilization through 3D aggregation, overcoming the limitations of small biopsy samples.
Data Source
AI summary
The present invention relates to a method for producing cartilage tissue by selecting and choosing from chondrocytes or spheroids, and use thereof as pharmaceutical composition, medicinal product or transplant. In particular, the invention relates to markers for identifying suitable chondrocytes for producing cartilage tissue, in particular for the purpose of transplantation.